To our knowledge, this study is the first one that investigated the composition of the Ig-bound stool microbiota fraction in advanced melanoma patients undergoing anti-PD-1 therapy and shed light on the association between intestinal immunity and clinical outcomes of the immunotherapy. This evidence concerns the gene PDCD1 and melanoma.